Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Search
Generic filters

New publication shows how Actiphage® test improves detection of bovine TB in blood

Actiphage® is a rapid blood test for the mycobacteria that cause bovine tuberculosis (bovine TB) and Johne’s disease. A new paper published in the journal of Microbial Biotechnology (3 December) describes how PBD Biotech developed the test.
  • December 3, 2019
  • Bovine TB, Research

Co-author Ben Swift explains that Actiphage was developed to offer an one-day test that is capable of detecting low levels of viable mycobacteria, “The Actiphage method offers the potential for rapid, inexpensive, sensitive detection of live mycobacteria in high-throughput format. It reduces the time to detection of the slow growing mycobacteria from months to hours.”

Mycobacteria are responsible for a wide range of diseases in humans and animals. Mycobacterium bovis (M.bovis) causes bovine TB in cattle, wildlife and a range of other species including pets. Mycobacterium avium subsp. paratuberculosis (MAP) causes Johne’s disease, a severe wasting disease in ruminants. MAP has also been associated with Crohn’s disease in humans, but a causative link has not yet been conclusively proven.

PBD Biotech has developed the Actiphage test for mycobacteria, in blood and milk, as a commercially available kit. The sensitivity and specificity of the new Actiphage test is a further improvement on the original phage-RPA, developed by the co-founders.

The paper ‘The development and use of Actiphage to detect viable mycobacteria from bovine tuberculosis and Johne’s disease infected animals’ co-authored by Drs Ben Swift and Cath Rees describes the method used.

The primary screening test for bovine TB in UK cattle is the single intradermal comparative cervical tuberculin test (SICCT) or tuberculin skin test. It is the internationally accepted standard for detecting M. bovis infection in live animals.

In the study, blood samples from cattle (n=41) found to be positive to M.bovis with SICCT were tested using both the original phage-RPA and the new Actiphage test.

Using the SICCT status as a comparator, the sensitivity of the Actiphage method was 95 % (95 % CI; 0.84 – 0.99) and specificity was 100 % (95% CI; 0.92 – 1).

These SICCT-positive animals had been classified post-mortem as either Visible (VL) or non-visible lesion (NVL), and the data showed that the Actiphage method detected mycobacteria in the blood of all (n=13) of the VL animals and 93 % (26/28) of the NVL animals. None of the animals in the negative control gave a positive result.

Swift concludes, “The sensitivity of the method allows detection of low numbers of viable cells in clinical blood samples and therefore has the potential to revolutionise disease management of mycobacterial infections.”

Actiphage is currently being trialled in the UK, Europe, USA and Canada, and PBD Biotech is working towards OIE (World Organisation for Animal Health) validation.

To find out more about Actiphage trials or get involved, please contact PBD Biotech.

Share:

Related posts

Loading...
Actiphage use as a DIVA test

Actiphage optimised to detect MAP in humans and to support use as ‘DIVA’

June 1, 2022
This is the first time Actiphage has been used to detect MAP in a human blood sample and also to identify a live infection in a vaccinated goat.
Actiphage use as a DIVA test

Actiphage optimised to detect MAP in humans and to support use as ‘DIVA’

June 1, 2022
This is the first time Actiphage has been used to detect MAP in a human blood sample and also to...
ECCMID

Actiphage® TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
ECCMID

Actiphage® TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
mycobacteria

Bacteriophage shows promise for detection and treatment of tuberculosis

March 7, 2022
Bacteriophages, viruses that infect and kill bacteria, offer the potential of a powerful tool for detecting and treating mycobacterial infections such as tuberculosis (TB), authors of a review in the journal Microorganisms* have reported.
mycobacteria

Bacteriophage shows promise for detection and treatment of tuberculosis

March 7, 2022
Bacteriophages, viruses that infect and kill bacteria, offer the potential of a powerful tool for detecting and treating mycobacterial infections...
Tomas Richardson

Disruptive phage technology attracts top scientist to PBD Biotech

January 18, 2022
“PBD Biotech has developed an exciting and potentially disruptive technology that uses bacteriophage to improve the molecular diagnosis of tuberculosis” says Dr Tomas Richardson.
Tomas Richardson

Disruptive phage technology attracts top scientist to PBD Biotech

January 18, 2022
“PBD Biotech has developed an exciting and potentially disruptive technology that uses bacteriophage to improve the molecular diagnosis of tuberculosis”...
1 2 … 7 Next »

developers of phage-based diagnostics

Contact Us

PBD Biotech Ltd
Link House, Elm Farm Park,
Great Green, Thurston,
Suffolk IP31 3SH,
United Kingdom

Registered Company Address
Ingenuity Centre,
University of Nottingham,
Innovation Park, Triumph Rd,
Nottingham NG7 2TU,
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

If you are going @CheshireShow there is an opportunity to talk to @ZaraBewizibet senior scientific adviser to Defra TB Policy. She is on the Cheshire Badger Vaccination Project @CBVP2021 stand. Good to see some joined up thinking #BadgerTrust #EndTB

Read More
PBD Biotech

@PeterMullowney Thank you @PeterMullowney for a very productive conference with many inspiring presentations. So good to see everyone @paratb2022

Read More
PBD Biotech

@1GarethWynJones @downtoearthuk_ @clovermad Mum always knows best 😉 Well done @clovermad for hosting.

Read More